<?xml version="1.0" encoding="UTF-8"?>

<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="shr-oncology-BrcaReceptorStatusCS"/>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml">
<p><b>SHR BrcaReceptorStatusCS CodeSystem</b></p>
<p>Classification of receptor status in breast cancer.</p>
</div>
  </text>
  <url value="http://standardhealthrecord.org/shr/oncology/cs/BrcaReceptorStatusCS"/>
  <identifier>
    <system value="http://standardhealthrecord.org"/>
    <value value="shr.oncology.BrcaReceptorStatusCS"/>
  </identifier>
  <version value="0.0.1"/>
  <name value="SHR BrcaReceptorStatusCS CodeSystem"/>
  <title value="SHR BrcaReceptorStatusCS CodeSystem"/>
  <status value="draft"/>
  <date value="2017-12-12"/>
  <publisher value="The MITRE Corporation: Standard Health Record Collaborative"/>
  <contact>
    <telecom>
      <system value="url"/>
      <value value="http://standardhealthrecord.org"/>
    </telecom>
  </contact>
  <description value="Classification of receptor status in breast cancer."/>
  <caseSensitive value="true"/>
  <content value="complete"/>
  <count value="4"/>
  <concept>
    <code value="luminal_A"/>
    <display value="Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy."/>
    <definition value="Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy."/>
  </concept>
  <concept>
    <code value="luminal_B"/>
    <display value="Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2."/>
    <definition value="Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2."/>
  </concept>
  <concept>
    <code value="HER2_positive"/>
    <display value="Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2."/>
    <definition value="Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2."/>
  </concept>
  <concept>
    <code value="Triple_negative"/>
    <display value="Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy."/>
    <definition value="Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy."/>
  </concept>
</CodeSystem>